Replies to post #279623 on Avid Bioservices Inc (CDMO)

[biopharm]

The principal investigator for the new five-year study is TSRI Associate Professor Hyeryun Choe, who will lead the effort to understand the virus’s mode of infection and how new therapies might interrupt it.

Hyeryun Choe knew exactly that the trouble began once PS flips...
And why has she not responded lately regarding the targeting of flipped PS, the 5 years is about up and again, all should email and ask Hyeryun Choe if the decision to shut down R&D at Peregrine or Avid Bioservices means she can't continue targeting flipped PS ?

.....especially now since we know for a fact C1Q is a major factor....and flipped PS must be targeted

Zika virus infection elicits auto-antibodies to C1q

Received:
27 November 2017

Accepted:
15 January 2018

Published online:
30 January 2018

Takaaki Koma, Veljko Veljkovic, Danielle E. Anderson, Lin-Fa Wang, Shannan L. Rossi, Chao Shan, Pei-Yong Shi, David W. Beasley, Natalya Bukreyeva, Jeanon N. Smith, Steven Hallam, Cheng Huang, Veronika von Messling & Slobodan Paessler
....
...

Abstract
Zika virus (ZIKV) causes mostly asymptomatic infection or mild febrile illness. However, with an increasing number of patients, various clinical features such as microcephaly, Guillain-Barré syndrome and thrombocytopenia have also been reported. To determine which host factors are related to pathogenesis, the E protein of ZIKV was analyzed with the Informational Spectrum Method, which identifies common information encoded by primary structures of the virus and the respective host protein. The data showed that the ZIKV E protein and the complement component C1q cross-spectra are characterized by a single dominant peak at the frequency F?=?0.338, suggesting similar biological properties. Indeed, C1q-specific antibodies were detected in sera obtained from mice and monkeys infected with ZIKV. As C1q has been known to be involved not only in immunity, but also in synaptic organization and different autoimmune diseases, a ZIKV-induced anti-C1q antibody response may contribute to the neurological complications. These findings might also be exploited for the design of safe and efficacious vaccines in the future.
...
...
https://www.nature.com/articles/s41598-018-20185-8

7) C1q binds PS and look who was involved? : ) keep digging deeper

C1q binds phosphatidylserine and likely acts as a multiligand-bridging molecule in apoptotic cell recognition

Helena Paidassi

Tacnet-Delorme P, Garlatti V, Darnault C, Ghebrehiwet B, Gaboriaud C, Arlaud GJ, Frachet P

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=116928014